The update interpretation of 2020 EAU bladder cancer guideline (Part Ⅰ) ——progress of muscle-invasive and metastatic bladder cancer / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 492-493, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-869692
ABSTRACT
The 2020 version of the European Association of Urology (EAU) guideline has updated the recommendations for the diagnosis and treatment of muscle-invasive bladder cancer and metastatic bladder cancer. The main changes include ① Pioglitazone use was significantly associated with increased risk of bladder cancer, so pioglitazone should not be prescribed for patients with bladder cancer or a history of bladder cancer. ②Progress involved molecular classification and molecular markers was made but could not be used in routine clinical practice at present. ③ Describes in detail of proper case and technical selection about pelvic organ-sparing radical cystectomy in female patients. ④Low molecular weight haparin usage for 4 weeks can reduce the incidence of postoperative venous thromboembolism. ⑤ PD-L1 positive patients with metastatic bladder cancer ineligible for cisplatin can use pembrolizumab or atezolizumab for first-line immunotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
Language:
Chinese
Journal:
Chinese Journal of Urology
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS